Inclusion Criteria:

          -  Age ≥18 years

          -  Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment

          -  Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL

          -  ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an
             attempt to quantify cancer patients' general well-being and activities of daily life.
             The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to
             2

          -  All study participants must be registered into the mandatory Revlimid REMS® program,
             and be willing and able to comply with the requirements of the REMS® program

          -  Females of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS® program.

          -  Men and Women of childbearing potential on appropriate contraception

          -  Adequate organ function

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Ability to swallow oral capsules/tablets

        Exclusion Criteria:

          -  Prior treatment for MCL with chemotherapy

          -  Pregnant or breastfeeding women

          -  Grade 2 or higher peripheral neuropathy

          -  Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study
             enrollment

          -  Significant cardiovascular disease

          -  Any condition that might significantly impair drug absorption as determined by the
             investigator

          -  Uncontrolled active systemic fungal, bacterial, viral, or other infection, or
             intravenous anti-infective treatment within 2 weeks before first dose of study drug

          -  History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug

          -  Concurrent participation in another clinical trial

          -  Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week
             prior to treatment initiation.

          -  Psychiatric illness or social situations that would limit compliance with study
             requirements

          -  Subject has known positivity to HIV

          -  Active infection with Hepatitis B or C virus as determined by a detectable viral load
             on PCR.

          -  Prior malignancy except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or any other cancer from which the subject has been
             disease free for ≥ 2 years or which will not limit survival to< 2 years.